TIGIT and neoplasm: In CT26 colon carcinoma, EMT6 breast carcinoma, MC38 colon carcinoma, and GL261 glioblastoma models, treatment with anti-TIGIT-blocking mAbs combined with anti-PD-1 or PD-L1-blocking mAbs leads to nearly complete remission of tumor growth, whereas the treatment of anti-TIGIT mAbs as a single agent presents limited efficacy [42,62,63].